Artios is a leading independent DDR Company with a strong pipeline of novel cancer therapies in development with first-in-class & best-in-class potential.
Location: United Kingdom, England, Cambridge
Employees: 51-200
Total raised: $268M
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | Life Scien... | lspvc.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 17.11.2025 | Series D | $115M | - |
| 27.07.2021 | Series C | $153M | - |
Mentions in press and media 7
| Date | Title | Description |
| 19.11.2025 | Artios Pharma Secures $115M to Advance Cancer Therapies | Artios Pharma, a UK-based biotech firm, has secured $115 million in Series D funding. The financing aims to boost the development of its precision cancer treatments. Focus on DNA damage response (DDR) is key. Funds will advance clinical tri... |
| 17.11.2025 | Artios Raises $115M in Series D Financing | Artios Pharma Limited, a Cambridge, UK-based biopharmaceutical company, raised $115M in Series D funding. The round was led by SV Health Investors and new investor RA Capital Management, with participation from Andera Partners, Avidity Part... |
| 17.11.2025 | Artios raises $115M Series D to accelerate first-in-class cancer therapies | Biotech company Artios today announced the successful close of an oversubscribed $115 million Series D financing. Artios is pioneering next-generation approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer a... |
| 17.11.2025 | €99 million Series D fuels Artios’ expansion of precision cancer treatment pipeline | Artios Pharma Limited, a British biopharmaceutical company committed to realising the therapeutic potential of targeting the DNA damage response (DDR) in cancer, today announced the successful close of an oversubscribed €99 million ($115 mi... |
| 24.09.2025 | Artios Receives U.S. FDA Fast Track Designation for alnodesertib in ATM-negative Metastatic Colorectal Cancer (mCRC) | CAMBRIDGE, United Kingdom and NEW YORK, September 24, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response (“DDR”) in cancer, today announced ... |
| 29.04.2025 | Artios Pharma Reports Differentiated Clinical Activity in STELLA Phase 1/2a Study for Lead Program ART0380 at the American Association for Cancer Research (AACR) Annual Meeting 2025 | CAMBRIDGE, United Kingdom and NEW YORK, April 29, 2025 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today reported encouraging data from its ongoing ST... |
| 10.08.2022 | Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer | CAMBRIDGE, UK and NEW YORK, USA, 10 August 2022: Artios Pharma Limited (Artios), a clinical stage biotech company pioneering the development of novel small molecule therapeutics that target the DNA damage response (“DDR”) process in order t... |